BL-M05D1

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameBL-M05D1
Drug Alias NameBL-M05D1BLM05D1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSichuan Baili Pharmaceutical Co LtdSystImmune
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBaili-Bio (Chengdu) Pharmaceutical Co LtdSystImmuneSichuan Baili Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A